Heterogeneity of Human Gliomas: Glutathione-S-Transferase Expression Profile During Disease Progression and Under Systemic Therapy.

Antineoplastic Agents / therapeutic use Astrocytoma / drug therapy Brain Neoplasms / drug therapy Cell Line, Tumor Disease Progression Glutathione S-Transferase pi / genetics Humans Isoenzymes Neoplasm Grading Transcriptome Treatment Outcome
Chemotherapy GSTP1 glioblastoma glutathione-S-transferase-π quantitative RT-PCR

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 15 01 2019
revised: 20 02 2019
accepted: 22 02 2019
entrez: 7 4 2019
pubmed: 7 4 2019
medline: 24 4 2019
Statut: ppublish

Résumé

The glutathione S-transferase pi gene (GSTP1) is a polymorphic gene encoding functionally different Gstp1 isoenzyme proteins. These seem to contribute to xenobiotic metabolism and might also play a role in susceptibility to cancer. The aim of this study was to elucidate the potential role of GSTP1 as a biomarker for disease progression and predictor of chemotherapeutic effect in glioma. Using quantitative real time PCR and western blotting analysis, a total of 61 astrocytic tumor samples from WHO grade II-IV were investigated. There were no differences in GSTP1 mRNA expression between diffuse astrocytomas, anaplastic astrocytomas, or GBM. No difference was seen between secondary GBM before and after radio-/chemotherapy. The expression of GSTP was highly heterogeneous within the surgical specimens. No significant differences in gene and protein expression were detected between the different types of gliomas, suggesting that glioma chemoresistance is probably multifactorial and GSTP1-independent.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
The glutathione S-transferase pi gene (GSTP1) is a polymorphic gene encoding functionally different Gstp1 isoenzyme proteins. These seem to contribute to xenobiotic metabolism and might also play a role in susceptibility to cancer. The aim of this study was to elucidate the potential role of GSTP1 as a biomarker for disease progression and predictor of chemotherapeutic effect in glioma.
MATERIALS AND METHODS METHODS
Using quantitative real time PCR and western blotting analysis, a total of 61 astrocytic tumor samples from WHO grade II-IV were investigated.
RESULTS RESULTS
There were no differences in GSTP1 mRNA expression between diffuse astrocytomas, anaplastic astrocytomas, or GBM. No difference was seen between secondary GBM before and after radio-/chemotherapy.
CONCLUSION CONCLUSIONS
The expression of GSTP was highly heterogeneous within the surgical specimens. No significant differences in gene and protein expression were detected between the different types of gliomas, suggesting that glioma chemoresistance is probably multifactorial and GSTP1-independent.

Identifiants

DOI: 10.21873/anticanres.13286 PMID: 30952719
pubmed: 30952719
pii: 39/4/1795
doi: 10.21873/anticanres.13286
doi:

Substances chimiques

Antineoplastic Agents 0
Isoenzymes 0
GSTP1 protein, human EC 2.5.1.18
Glutathione S-Transferase pi EC 2.5.1.18

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1795-1805

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Robin Tjiong (R)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany.

Pantelis Stavrinou (P)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany.

Gabriele Röhn (G)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany.

Boris Krischek (B)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany.

Arend Koch (A)

Department of Neuropathology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Roland Goldbrunner (R)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany.

Marco Timmer (M)

Laboratory of Neurooncology and Experimental Neurosurgery, Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, University of Cologne, Cologne, Germany marco.timmer@uk-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Alkyl et aryl transferases › Glutathione transferase › Glutathione S-transferase pi › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Isoformes de protéines › Isoenzymes › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Diagnostic › Pronostic › Grading des tumeurs › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Transcriptome › Heterogeneity of Human Gliomas:...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Heterogeneity of Human Gliomas:...